Valsartan is an oral medication that belongs to a class of medications called angiotensin receptor blockers (ARBs). It is a specific angiotensin II antagonist with oral activity, which acts on the AT1 subtype. Binding of angiotensin to its receptors causes the blood vessels to narrow (vasoconstriction), which leads to an increase in blood pressure (hypertension). Valsartan blocks angiotensin II receptors. By blocking the effects of angiotensin, valsartan can dilate blood vessels and lower blood pressure without affecting the pulse rate. The affinity of valsartan for the AT1 receptor is much higher than that for the AT2 receptor (about 20,000 times). It does not bind to or block other hormone receptors or ion channels that are known to be important for cardiovascular regulation.
Dosage & Administration
Hypertension: The usual dose of Valsartan is 80 to 160 mg once daily. The maximum
dose is 320 mg daily. Maximum blood pressure reduction occurs within 4
Heart failure: The usual dose is 40 mg twice daily and may be increased to 80-160 mg twice daily.
Post-Myocardial Infarction: The initial dose after myocardial infarction is 20 mg twice daily. The dose should be increased with a target of 160 mg daily if tolerated without side effects.
Administration of Valsartan with food decreases the absorption of Valsartan by about 40%, so it should be taken on an empty stomach. No initial dosage adjustment is required for elderly patients with mild to moderate renal and hepatic insufficiency.
No clinically significant drug interactions were found. Compounds that have been studied in clinical trials include cimetidine, warfarin, furosemide, digoxin, atenolol, indomethacin, hydrochlorothiazide, amlodipine, and glibenclamide.
Valsartan is not extensively metabolized, and clinically relevant drug interactions appear as induction or inhibition. metabolic. it is not expected to produce the cytochrome P450 system. Although valsartan is highly bound to plasma proteins, in vitro studies have not shown any interaction at this level with molecules that are highly bound to a number of proteins (such as diclofenac, furosemide, and warfarin). Simultaneous use of potassium-sparing diuretics (such as spironolactone, triamterene, amiloride), potassium supplements, or potassium-containing salt substitutes may lead to an increase in serum potassium. If you think it is necessary to use a combination of drugs, caution is advised
Valsartan is contraindicated in patients allergic to any component of this product.
Valsartan is generally well tolerated and has few side effects. The most common side effects include headache, dizziness, fatigue, abdominal pain, cough, diarrhea, and nausea. Patients may also experience hyperkalemia, impotence, decreased kidney function, allergic reactions, dyspnea, constipation, back pain, muscle cramps, rash, anxiety, insomnia, and dizziness. If the patient is taking diuretics and valsartan at the same time, hypotension may also occur.
Pregnancy: Valsartan should not be
used during pregnancy because it can cause fetal injury or even death in the
second and third trimester. When pregnancy is detected, valsartan treatment
should be stopped as soon as possible.
Breastfeeding mothers: Whether valsartan is excreted in human milk is unclear. Due to the possibility of adverse reactions in breastfeeding infants, the importance of the drug to the mother should be considered and the decision to stop breastfeeding or medication should be stopped.
Hepatic impairment: Since most of
valsartan is excreted by bile, patients with mild to moderate hepatic
impairment (including obstructive biliary disease) should be used with
Impaired renal function: Patients
with pre-existing impaired renal function may need to reduce or interrupt the
Heart failure and myocardial infarction: Patients with heart failure and myocardial infarction should be cautious when starting treatment.
Angiotensin-ll receptor blocker
Store between 15-30° C. Protect from moisture and heat.